Initial Single-center Experience of PIPAC in Patients With Unresectable Peritoneal Metastasis.

Abstract Introduction Peritoneal carcinomatosis remains a condition with poor prognosis and limited therapeutic options. Pressurized intrapertioneal aerosol chemotherapy (PIPAC) has been developed as a new tool for delivering intraperitoneal chemotherapy with low morbidity. The aim of this study was to evaluate the initial experience of PIPAC in patients with peritoneal carcinomatosis at our hospital. Methods A prospective study between January 2019 and February 2020 was carried at a tertiary public hospital. Primary tumor, ascites volume, PCI, chemotherapy regimen, operative time, morbidity, length of hospital stay and mortality were recorded for analysis. Results We analyzed 9 PIPAC procedures performed in 5 patients. Median PCI was 27.6 (24–35). Median surgical time was 93 min (70–125). Only one adverse event occurred out of 9 procedures (Clavien-Dindo II). Median length of hospital stay was 2 days (1–4). Mortality was 0%. Conclusion PIPAC seems to be a feasible and safe procedure to treat peritoneal carcinomatosis, with low morbidity and short hospital stay.